Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Wyszukujesz frazę "atorvastatin" wg kryterium: Wszystkie pola


Wyświetlanie 1-6 z 6
Tytuł:
Atorvastatin adsorption studies on chitosans in an in vitro pharmaceutical model
Autorzy:
Meler, Jan
Grimling, Bożena
Szcześniak, Maria
Karolewicz, Bożena
Biernat, Paweł
Powiązania:
https://bibliotekanauki.pl/articles/1034415.pdf
Data publikacji:
2018
Wydawca:
Sieć Badawcza Łukasiewicz - Polskie Towarzystwo Chitynowe
Tematy:
Atorvastatin
adsorption
chitosan
Opis:
During the pharmacological therapy of specific diseases, drugs are used which, with other preparations or foods, can create connections, in many cases changing or even blocking their action. On the other hand, the use of unsuitable polymers as excipients may result in drug-polymer incompatibilities. Interactions consisting mainly of the occurrence of the adsorption phenomenon and on the formation of complex bonds that reduce the effect of the drugs are of particular importance. The aim of the study was to investigate whether the active substance atorvastatin is incompatible with dietary supplements containing chitosan. The phenomenon of the adsorption of the drug was examined using a static model of a pharmaceutical gastrointestinal tract, in the concentration range generally ingested in a single dose. Measurement results of the amount of bound drug were used to determine the average percentage of adsorbed drug dose. The results of the study prove that the anticholinesterase drug is adsorbed on chitosan in the pH ranges used, and that the binding capacity depends on the chitosan variety, which indirectly affects the reaction of the environment. It was observed that the average size of sorption depending on the chitosan variety ranged from 38% to 86%. The fact that the lowest value of adsorption was at pH 6.4 can be explained by the chemical properties of chitosan, which shows a charge only at pH >6.7. Under such conditions, the phenomenon of electrostatic adsorption may occur in relation to the healing substances of weak acids. At a pH above 7.6, corresponding to the intestinal fluid-filled intestine, the mean sorption for the highest dose of chitosan was from 38–86%. The increase in the adsorbed amount of anticholinesterase drugs on the polymer along with the increase in pH from 7.6 to 8.0 can be explained by the chitosan swelling properties, which increase with an increase in the pH. As a result, the specific surface area of the polymer and its sorption capacity increase. Based on the above considerations, it can be concluded that there is an antagonistic interaction between the drug and the polymer studied, which involves the adsorption of a drug from this group on the polymer (chitosan) and a decrease in its bioavailability
Źródło:
Progress on Chemistry and Application of Chitin and its Derivatives; 2018, 23; 140-148
1896-5644
Pojawia się w:
Progress on Chemistry and Application of Chitin and its Derivatives
Dostawca treści:
Biblioteka Nauki
Artykuł
Tytuł:
Atorvastatin improves tubular status in non-diabetic patients with chronic kidney disease - placebo controlled, randomized, cross-over study
Autorzy:
Renke, Marcin
Tylicki, Leszek
Rutkowski, Przemysław
Neuwelt, Alexander
Larczyński, Wojciech
Ziętkiewicz, Marcin
Aleksandrowicz, Ewa
Łysiak-Szydłowska, Wiesława
Rutkowski, Bolesław
Powiązania:
https://bibliotekanauki.pl/articles/1040322.pdf
Data publikacji:
2010
Wydawca:
Polskie Towarzystwo Biochemiczne
Tematy:
proteinuria
kidney
tubular injury
chronic kidney disease
Atorvastatin
Opis:
Background. There is evidence that dyslipidemia is associated with chronic kidney disease (CKD) and it has been implicated in the progression of renal damage. Optimal management of dyslipidemia should therefore lead to renal benefits. A number of experimental models demonstrate a beneficial effect of statins in ameliorating renal damage. However, the exact mechanism by which statins protect against renal damage remains unclear. Methods. In a placebo-controlled, randomized, cross-over study we evaluated the influence of atorvastatin (ATO) 40 mg/day added to the renin-angiotensin-aldosterone systeme (RAAS) blockade on proteinuria and surrogate biomarkers of tubular damage or injury in 14 non-diabetic patients with proteinuria (0.4-1.8 g per 24 h) with normal or declined kidney function (eGFR 55-153 ml/min). In the eight-week run-in period, therapy using angiotensin converting enzyme inhibitors (ACEI) and/or angiotensin II subtype 1 receptor antagonists (ARB) was adjusted to achieve a blood pressure below 130/80 mm Hg. Next, patients were randomly assigned to one of two treatment sequences: ATO/washout/placebo or placebo/washout/ATO. Clinical evaluation and laboratory tests were performed at the randomization point and after each period of the study. The primary end point of this study was a change in proteinuria measured as 24-h urine protein excretion (DPE). Secondary end points included urine N-acetyl-β-d-glucosaminidase (NAG) and α1-microglobulin (α1m) excretion. Results. The ATO therapy significantly reduced urine excretion of α1m (p=0.033) and NAG (p=0.038) as compared to placebo. There were no differences in proteinuria, blood pressure, eGFR and serum creatinine between the ATO and placebo groups. Conclusion. Atorvastatin treatment is safe and improves biomarkers of tubular damage or injury in non-diabetic patients with CKD.
Źródło:
Acta Biochimica Polonica; 2010, 57, 4; 547-552
0001-527X
Pojawia się w:
Acta Biochimica Polonica
Dostawca treści:
Biblioteka Nauki
Artykuł
Tytuł:
The influence of elastin degradation products, glucose and atorvastatin on metalloproteinase-1, -2, -9 and tissue inhibitor of metalloproteinases-1, -2, -3 expression in human retinal pigment epithelial cells
Autorzy:
Dorecka, Mariola
Francuz, Tomasz
Garczorz, Wojciech
Siemianowicz, Krzysztof
Romaniuk, Wanda
Powiązania:
https://bibliotekanauki.pl/articles/1039285.pdf
Data publikacji:
2014
Wydawca:
Polskie Towarzystwo Biochemiczne
Tematy:
metalloproteinase
TIMP
atorvastatin
HRPE
Opis:
Purpose: Hyperglycemia and increased concentrations of elastin degradation products (EDPs) are common findings in patients with diabetes, atherosclerosis and hypertension. The aim of this study was to assess the influence of high glucose, EDPs and atorvastatin on MMP-1, MMP-2, MMP-9 and TIMP1-3 gene expression in human retinal pigment epithelial cells (HRPE) in vitro. Method: HRPE were cultured for 24 hours with the substances being tested (glucose, EDPs), alone or in combination. Additionally, the cells were treated with atorvastatin in two different concentrations (1 or 10 μM). After incubation, total cellular RNA was extracted and used for gene expression evaluation. Gene expression was measured using the real-time RT-PCR technique. Results: Glucose, EDPs and atorvastatin had no impact on TIMP-1 and TIMP-3 expression. HRPE cells treated with glucose or EDPs with the addition of atorvastatin had a statistically significant decrease of TIMP-2 expression; glucose alone decreased MMP-1 expression. Atorvastatin decreased expression of all assessed genes, except TIMP-1 and TIMP-3 in a dose-dependent manner. Conclusions: Our results confirm the importance of MMPs and TIMPs in retinal vascular biology. Atorvastatin-induced MMPs gene expression can deeply affect extracellular matrix turnover, which may play an important role in the progression of ocular diseases.
Źródło:
Acta Biochimica Polonica; 2014, 61, 2; 265-270
0001-527X
Pojawia się w:
Acta Biochimica Polonica
Dostawca treści:
Biblioteka Nauki
Artykuł
Tytuł:
Interindividual variability of atorvastatin treatment influence on the MPO gene expression in patients after acute myocardial infarction
Autorzy:
Sygitowicz, Grażyna
Maciejak, Agata
Piniewska-Juraszek, Joanna
Pawlak, Maciej
Góra, Monika
Burzyńska, Beata
Dłużniewski, Mirosław
Opolski, Grzegorz
Sitkiewicz, Dariusz
Powiązania:
https://bibliotekanauki.pl/articles/1038846.pdf
Data publikacji:
2016
Wydawca:
Polskie Towarzystwo Biochemiczne
Tematy:
MPO gene expression
myeloperoxidase
C-reactive protein
atorvastatin
acute myocardial infarction
Opis:
Myeloperoxidase (MPO) and C-reactive protein (CRP) may play critical roles in generation of oxidative stress and the development of the systemic inflammatory response. The aim of the study was to determine the effect of atorvastatin therapy on the MPO gene expression and its plasma level in relation to lipids level lowering and an anti-inflammatory response in patients after acute myocardial infarction. The research material was represented by 112 samples. Thirty-eight patients with first AMI receiving atorvastatin therapy (40 mg/day) and followed up for one month were involved in the study. The relative MPO gene expression in peripheral blood mononuclear cells (PBMCs) was examined using RT-qPCR in 38 patients before-, 38 patients after-therapy and in 36 patients as the control group. The plasma concentrations of MPO and serum concentrations of biochemical parameters were determined using commercially available diagnostic tests. After one month of atorvastatin therapy, in 60.5% patients a decrease of MPO gene expression, whereas in 39.5% patients an increase, was observed. The plasma MPO levels behaved in the same way as the MPO gene expression. However, the serum lipids and CRP concentrations were significantly lower after one month of atorvastatin therapy in both groups of patients - with decreased and increased MPO gene expression. Atorvastatin exhibited a different effect on MPO gene expression and its plasma level. Short-term atorvastatin therapy resulted in lipid lowering and anti-inflammatory activity in patients after AMI, independently of its effect on MPO gene expression. The molecular mechanisms of this phenomenon are not yet defined and require further research.
Źródło:
Acta Biochimica Polonica; 2016, 63, 1; 89-95
0001-527X
Pojawia się w:
Acta Biochimica Polonica
Dostawca treści:
Biblioteka Nauki
Artykuł
Tytuł:
Hypolipidemic action of rutin on triton WR-1339-induced hyperlipidemia in rats
Autorzy:
Livingston Raja, N.R.
Nair, A.R.
Senthilpandian, S.
Ravi, V.
Powiązania:
https://bibliotekanauki.pl/articles/2098294.pdf
Data publikacji:
2020
Wydawca:
Instytut Medycyny Wsi
Tematy:
rutin
flavonoids
triglyceride
atorvastatin
Triton WR-1339
hyperlipidemia
cholesterol
rat
Opis:
Introduction and objective. Hyperlipidemia is considered as a serious communal problem in developed countries, caused by an excess level of cholesterol in blood circulation. It leads to chronic illness and even death in human beings. As the currently available drugs cause unexpected side-effect, the aim of this study is to concentrate on naturally occurring flavonoids which can potentially provide defensive and therapeutic effects in atherosclerosis diseases, and investigate the hypolipidemic effect of rutin on Triton WR-1339 triggered hyperlipidemia in a rat blood sample. Materials and method. Rats were randomly prearranged into five different groups of five rats each. Group-I was the non-disease control and administered normal saline. Group-II was the atherogenic control, administered Triton WR 1339 (200 mg/kg BW). Group-III was standard and received Atorvastatin. The last two groups (IV, V) were tested (I&II) by administering administered Rutin (40 mg/kg, 80 mg/kg) orally. The test material (I&II) and the standard drug were administered for seven days. After the last dose, blood samples were collected and the lipid levels estimated in the blood samples. Results. Rats treated with rutin flavonoid at a dose of 40 mg/kg & 80mg/kg exhibited a reduction in Total Cholesterol, Triglycerides, Low Density Lipoprotein (LDL) and Very Low Density Lipoprotein (VLDL). Rutin also increases the High Density Lipoprotein (HDL), compared with control rats. Rutin treated rats exhibited dose-dependent hypolipidemic activity. The protection percentage of rutin against hyperlipidemia was observed as 41.89%, 55.57% whereas the atorvastatin treated group protection was observed at 60.63%. Conclusions. The results of the study revealed that rutin showed a significant hypolipidemic effectiveness on Triton WR- 1339 induced hyperlipidemia in rats.
Źródło:
Journal of Pre-Clinical and Clinical Research; 2021, 15, 2; 51-55
1898-2395
Pojawia się w:
Journal of Pre-Clinical and Clinical Research
Dostawca treści:
Biblioteka Nauki
Artykuł
Tytuł:
Influence of some statins on bacteria and actinomyces
Wpływ niektórych statyn na bakterie i promieniowce
Autorzy:
Targonski, R.
Kucharski, J.
Wyszkowska, J.
Powiązania:
https://bibliotekanauki.pl/articles/14254.pdf
Data publikacji:
2006
Wydawca:
Uniwersytet Warmińsko-Mazurski w Olsztynie / Polskie Towarzystwo Magnezologiczne im. Prof. Juliana Aleksandrowicza
Tematy:
atorvastatin
bacteria
statin
simvastatin
fluvastatin
Bacillus subtilis
Bacillus cereus
Proteus vulgaris
Pseudomonas fluorescens
Escherichia coli
actinomycete
Opis:
In an in uitro experiment the effect of three statins (atorvastatin [Sortis], simvastatin [Zocor], fluvastatin [Lescol]) on the growth of 5 bacterial strains Bacillus subtilis, Bacillus cereus, Proteus vulgaris, Pseudomonas fluorescens, Escherichia coli and 4 saprophytic actinomycetes Streptomyces longisporoflavus, Streptomyces intermedius, Streptomyces odoriver, Streptomyces viridis was tested. The experiments were carried out on solidified substrata with microorganisms covered with filter paper rings soaked with aqueous solution of every tested statin used in different concentrations. It was found that examined substances can inhibit the growth of certain saprophytic microorganisms. Fluvastatin rather than simvastatin or atorvastatin produces stronger effect on bacteria and actinomycetes.
W doświadczeniu in vitro badano wpływ trzech statyn (atorwastatyny [Sortis], simwastatyny [Zocor], fluwastatyny [Lescol]) na rozwój 5 szczepów bakterii: Bacillus subtilis, Bacillus cereus, Proteus vulgaris, Pseudomonas fluorescens, Escherichia coli oraz 4 saprofitycznych promieniowców: Streptomyces longisporoflavus, Streptomyces intermedius, Streptomyces odoriver, Streptomyces viridis. Doświadczenia prowadzono na zestalonych podłożach, przy czym mikroorganizmy przykrywano krążkami papieru filtrującego, nasączonymi wodnym roztworem poszczególnych statyn w różnych stężeniach. Stwierdzono, że badane substancje mogą ograniczać rozwój pewnych mikroorganizmów saprofitycznych. Fluwastatyna miała silniejszy wpływ hamujący na bakterie i promienowce niż simwastatyna lub atorwastatyna.
Źródło:
Journal of Elementology; 2006, 11, 4
1644-2296
Pojawia się w:
Journal of Elementology
Dostawca treści:
Biblioteka Nauki
Artykuł
    Wyświetlanie 1-6 z 6

    Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies